## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applic	ants:	Thompson, et al.		
	4-CYC	to be assigned  CLOALKYLAMINOPYRAZOLO PYRIMIDINE  VNR2B ANTAGONISTS	Art Unit: _	

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- 4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

MEREBY CERTIFY THAT THIS CORRESPONDENCE IS  With the Unit BEING DEPOSITED WITH THE UNITED STATES POSTAL  an envelope	tify that this correspondence is being deposited ted States Postal Service as first class mail in addressed to: Commissioner for Patents, 450, Alexandria, Virginia 22313-1450, on the ring below.  MERCK & CO., INC.  Date
--	---

RELATED APPLICATION

## INFORMATION DISCLOSU

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

	NELATED AF	MELATED AFFEIGATION			
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE			
If this is inconvenient, additional copies will be submitted upon red	quest.				
6. In accordance with 37 C.F.R. 1.97, (check one)					
the attached information is filed within three months of the filing	ng date of the captioned case.				
the attached information is filed more than three months after Office Action on the merits.	the filing date but prior to the	mailing of a first			
the attached information is filed before the mailing of a first Of examination under §1.114.	ffice action after the filing of a	request for continued			
the attached information is being filed more than three months Office Action on the merits, but before the mailing date of a Fi		_			

otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p). each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement. each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement. no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement. Respectfully submitted,

By: Mitul I. Desai

For Applicant(s) Attorney

Reg. No. 46,661

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-<u>3190</u>

Date: February 14, 2006

MEDROGEROUS TO FER THE

Approved for use through 7/31/2006. OMB 0651-0031 SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure Statement by Applicant Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

					Tatem and Tracement Office, C.O. Dall Tate Total Co. Tatement		
Su	ubstitute for form 1449A/PTO			COMPLETE IF KNOWN			
•	NFORMATION I	DIS	CLOSURE	Application Number	PCT/US2004/025961		
	OF A OFTEN WITH NOTE TON 7	A TO	DIICANT	Filing Date			
5	TATEMENT BY	AP	PLICANI	First Named Inventor	Thompson, et al.		
				Group Art Unit			
	(use as many sheets	as n	ecessary)	Examiner Name			
Sheet	1	of	2	Attorney Docket Number	21494YP		
					·		

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	U.S. Patent Document	Kind Code (known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
	-						

			FOREI	GN PATENT	DOCUMENTS	
Examiner Initials*	Cite No.	Office	Foreign Patent Documer Number	t Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
				(if known)		MM-DD-YYYY
	A1		EP 0 641 781 A		Yoshitomi Pharmaceuticals	03/08/1995
	A2		EP 0 729 758 A		Pfizer Inc.	09/04/1996
	A3		WO 98/35048 A		Shokat Kevan M.	08/13/1998
	<u> </u>					

Examiner Signature

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of

				COMPLETE IF KNOWN			
•	ubstitute for form 1449B/PTO [NFORMATION]	DIS	CLOSURE	Application Number	PCT/US2004/025961 ,.		
				Filing Date	(* ) (* ) (* ) (* ) (* ) (* ) (* ) (* )		
2	STATEMENT BY	AP	PLICANT	First Named Inventor	Thompson, et al.		
			,	Group Art Unit			
	(use as many sheets	as r	necessary)	Examiner Name			
Sheet	2	of	2	Attorney Docket Number	21494YP		

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.						
	A4	Anthony C. Bishop, et al. "Design of allele-specific inhibitors to probe protein kinase signaling" Current Biology, Vol. 8, No. 5, 1998, pages 257-266						
	1							

	Examiner Signature		Date Considered	
--	-----------------------	--	--------------------	--